A Practical Approach in Refining Binary Outcome for Treatment Effect of COVID-19 According to Geographical Diversity

A Practical Approach in Refining Binary Outcome for Treatment Effect of COVID-19 According to Geographical Diversity

The recent COVID-19 pandemic has drawn attention to health and economics worldwide. Initially, diseases only ravage local populations, while a pandemic could aggravate global economic burdens. Lopinavir/Ritonavir is an anti-HIV drug that was used on small scale patients during SARS, but its effectiv...

Full description

Bibliographic Details
Main Author:	I-Shiang Tzeng
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Tropical Medicine and Infectious Disease
Subjects:	COVID-19 efficacy safety Lopinavir/Ritonavir small number of studies bias geographical diversity
Online Access:	https://www.mdpi.com/2414-6366/8/2/83

Similar Items

Atazanavir efficacy in covid-19: A retrospective protease inhibitors comparative study 2020
by: Ahmad Alikhani, et al.
Published: (2022-01-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection.
by: A. Yu. Sambyalova, et al.
Published: (2021-12-01)

Efficacy and Safety of Lopinavir/Ritonavir for Treatment of COVID-19: A Systematic Review and Meta-Analysis
by: Saad Alhumaid, et al.
Published: (2020-11-01)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
by: Motahareh Amirizadeh, et al.
Published: (2023-01-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)
by: Gbenga A. Adefolaju, et al.
Published: (2015-11-01)

Thirteen-year viral suppression and immunologic recovery of LPV/r-based regimens in pediatric HIV treatment: a multicenter cohort study in resource-constrained settings of China
by: Xiaojie Lao, et al.
Published: (2023-12-01)

Potential clinically significant life-threatening drug–drug interactions of lopinavir and ritonavir used in the treatment of COVID-19
by: Mohitosh Biswas, et al.
Published: (2020-01-01)

Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
by: Xiaojie Huang, et al.
Published: (2019-12-01)

Clinical evaluation of selected Pharmacological Treatments used for Coronavirus (COVID-19) pandemic
by: hasan mohammed altemimy
Published: (2020-06-01)

Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives
by: Simone Meini, et al.
Published: (2020-06-01)

COVID-19: An Update about the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-05-01)

COVID-19: A Brief Overview of the Discovery Clinical Trial
by: Jean Jacques Vanden Eynde
Published: (2020-04-01)

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection
by: Irin Tanaudommongkon, et al.
Published: (2021-06-01)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
by: Alexander M. Kaizer, et al.
Published: (2023-03-01)

Melatonin and alpha lipoic acid restore electrolytes and kidney morphology of lopinavir/ritonavir-treated rats
by: Elias Adikwu, et al.
Published: (2020-01-01)

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
by: B. K. Romanov
Published: (2020-09-01)

Therapeutic Potential of Targeting the Cytochrome P450 Enzymes Using Lopinavir/Ritonavir in Colorectal Cancer: A Study in Monolayers, Spheroids and In Vivo Models
by: Maryam Alaei, et al.
Published: (2023-08-01)

Evaluating the Effects of Umifenovir Compared to Lopinavir/Ritonavir in the Management of Patients with COVID-19: A Randomized Controlled Trial
by: Farzaneh Dastan, et al.
Published: (2022-12-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

Health Outcomes at School Age among Children Who Are HIV-Exposed but Uninfected with Detected Mitochondrial DNA Depletion at One Year
by: Audrey Monnin, et al.
Published: (2020-11-01)

Adverse pregnancy outcomes associated with antiretroviral therapy initiated before pregnancy and during pregnancy: a retrospective study in Hubei province, China
by: Yuting Tan, et al.
Published: (2023-05-01)

Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
by: Milo Gatti, et al.
Published: (2021-02-01)

Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan
by: A. A. Zurdinova, et al.
Published: (2021-12-01)

Development of Advanced 3D-Printed Solid Dosage Pediatric Formulations for HIV Treatment
by: Azizah M. Malebari, et al.
Published: (2022-03-01)

Mitochondrial DNA Parameters in Blood of Infants Receiving Lopinavir/Ritonavir or Lamivudine Prophylaxis to Prevent Breastfeeding Transmission of HIV-1
by: Audrey Monnin, et al.
Published: (2020-09-01)

SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches—Insights into Chemical Structure—Biological Activity and Toxicological Screening
by: Cristina Adriana Dehelean, et al.
Published: (2020-07-01)

Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review
by: Victoria Gil Martínez, et al.
Published: (2021-07-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

COVID-19 possible medical treatments
by: Marzieh Mohammadi, et al.
Published: (2021-01-01)

Safety of Drugs Used during the First Wave of COVID-19: A Hospital-Registry-Based Study
by: Cristina Aguilera, et al.
Published: (2022-07-01)

Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report
by: Xuechun Mu, et al.
Published: (2023-10-01)

An early assessment of the efficacy of medicines in the treatment of patients with COVID-19
by: A. S. Kolbin
Published: (2020-05-01)

Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs
by: Nathalie Vernaz, et al.
Published: (2020-12-01)

The interplay of poorly soluble drugs in dissolution from amorphous solid dispersions
by: Marcel Kokott, et al.
Published: (2024-06-01)

Systemic review and meta-analysis to evaluate therapeutic effectiveness of interferon beta-1b in hospitalized COVID-19 patients
by: Greeshma Sai Sree Nayudu, et al.
Published: (2023-01-01)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
by: M. Karolyi, et al.
Published: (2022-07-01)

Prevalence and Influencing Factors of Immunological Non-response in HIV/AIDS Patients with Second-line Antiretroviral Therapy
by: Dongli WANG, Yanke AI, Jun YUAN, Xiuxia MA, Huijun GUO, Qianlei XU, Yantao JIN
Published: (2022-10-01)